Kornimate/medical-research-clean huggingface dataset:
the effect of dapagliflozin on the short-term prognosis of patients with acute myocardial infarction

Conditions: Myocardial Infarction; Diabete Type 2; Glucose Intolerance

Summary: dapagliflozin is one of the sglt-2 inhibiters. recent clinical trials have demonstrated that sglt-2 inhibitors are effective for treating heart failure. the dapa-hf clinical trial has demonstrated that the effects of empagliflozin and dapagliflozin improve renal outcomes and reduce all-cause and cardiovascular death in patients with hfref\[1\]. however, its effect on myocardial infarction, the most common disease leading to death in the population, has not been evaluated sufficiently. a meta-analysis has demonstrated that compared with the control, sglt2 inhibitor is associated with a reduction in the incidence of major adverse cardiovascular events (maces), myocardial infarction, cardiovascular mortality and all-cause mortality\[2\]. it seems that dapagliflozin might be effective for patients with acute myocardial infarction based on these studies. thus, this study aims to evaluate the effect of dapagliflozin on short-term prognosis in patients with acute myocardial infarction compared to placebo. 1. faiez zannad, joão pedro ferreira, stuart j pocock et el. sglt2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the emperor-reduced and dapa-hf trials. lancet. 2020 sep 19;396(10254):819-829. 2. cai-yan zou, xue-kui liu, yi-quan sang et el. effects of sglt2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. medicine (baltimore). 2019 dec;98(49):e18245.


Eligibility criteria:
inclusion criteria: 1. diagnosed with acute mi, either stemi or nstemi, according to the fourth universal definition of mi (thygesen et al. 2019), disease onset within 7 days. 2. previously diagnosed with type2 diabetes mellitus, newly diagnosed type2 diabetes according to ada criteria or glucose intolerance. 3. capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and the protocol. exclusion criteria: 1. patients diagnosed with type 1 diabetes mellitus. 2. patients with renal dysfunction. (gfr\<90mmol/l). 3. patients who have recently undergone immunosuppressive therapy. 4. patients with a history of recurrent urinary tract infections. 5. patients who are known to be allergic to sglt-2 inhibitors. 6. patients who are hemodynamically unstable. 7. chronic symptomatic heart failure within the last year and known reduced ejection fraction (lvef≤40 %), documented before the current mi hospitalization. 8. severe hepatic impairment (child-pugh class c) at the time of inclusion into the trial. 9. any other non cardiovascular diseases, such as active malignancy requiring treatment at the time of screening or with a life expectancy of fewer than two years based on the investigator´s clinical judgment. 10. currently on treatment with a sodium-glucose co-transporter 2 inhibitor (sglt2-inhibitor).

Keywords: myocardial infarction dapagliflozin mace events
video treatment for amblyopia

Conditions: Amblyopia

Summary: the purpose of this study is to determine whether viewing asynchronous movies leads to better visual outcomes in young children with amblyopia than standard-of-care occlusion therapy with an adhesive patch and whether this is associated with better adherence to treatment.

this is a single-site randomized clinical trial to compare treatment of amblyopia by viewing asynchronous movies to standard-of-care occlusion therapy with an adhesive patch. participants will be referred from local pediatric ophthalmologists. following informed consent, children will complete baseline testing to confirm eligibility and provide pre-treatment measurements of visual acuity, suppression, stereoacuity, motor skills, self-perception, and quality of life. eligible children will then be randomly allocated to either patch-free occlusion therapy or standard-of-care occlusion therapy with an adhesive patch. children will participate in their assigned occlusion therapy at home for 6 weeks (primary outcome). adherence will be objectively monitored. vision will be re-assessed at 2 and 4 weeks and all tests will be repeated at 6 weeks. the asynchronous movie group will have an option to continue for and additional 2 or 4 weeks (10 weeks total). the standard-of-care occlusion group will be offered the opportunity to use the movie treatment at the 6 week visit through 10 weeks. children who choose to remain in the study beyond the 6 week primary outcome visit will have vision reassessed at 8 and 10 weeks. the primary analysis will be a comparison of improvement in amblyopic eye visual acuity (baseline-6 weeks) between the movie group and the standard-of-care patching group. secondary analyses will include comparisons of adherence to each treatment, comparison of the proportion of children in each group with visual acuity ≤0.1 logmar (recovered) at 6 weeks and 95% cis, comparisons of changes in extent of suppression, depth of suppression, stereoacuity, motor skills standard scores, self-perception scores, and pedeyeq domain scores. associations among hours of treatment, changes in visual acuity, suppression, and stereoacuity, will be explored and modeled for dose-response relationships. in exploratory analyses, we will examine whether there are additional improvements in visual acuity, suppression, or stereoacuity between 6 and 10 weeks for the movie group (8 and 10 weeks means and 95% cis).

Eligibility criteria:
inclusion criteria: * aged 3-8 years (3-7 primary cohort) * male and female * strabismic, anisometropic, or combined mechanism amblyopia (visual acuity 0.3-0.8 logmar) * interocular visual acuity difference ≥0.3 logmar * wearing glasses (if needed) for a minimum of 8 weeks with no change in visual acuity at 2 visits ≥4 weeks apart * child's ophthalmologist and family willing to forgo standard patching treatment during the study exclusion criteria: * prematurity ≥8 wk * coexisting ocular or systemic disease * developmental delay * strabismus \>5 pd * myopia \> -3.00d
study of cb-839 in combination w/ paclitaxel in participants of african ancestry and non-african ancestry with advanced triple negative breast cancer (tnbc)

Conditions: Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer

Summary: cx-839-007 is an open-label phase 2 study of the combination of cb-839 with paclitaxel in participants of african ancestry and non-african ancestry with advanced triple negative breast cancer. multiple single-arm cohorts will be enrolled in which 800 mg twice daily (bid) cb-839 will be administered in combination with the full approved dose of paclitaxel.

participants will be enrolled into 4 cohorts, as follows: * cohort 1: patients of african ancestry with 2 or more lines of prior therapy for metastatic disease * cohort 2: patients of african ancestry with no prior lines of therapy for metastatic disease * cohort 3: same as cohort 1 but in patients of non-african ancestry * cohort 4: same as cohort 2 but in patients of non-african ancestry

Eligibility criteria:
key inclusion criteria: * meets criteria for 1 of the 4 defined study cohorts * tnbc, defined as estrogen receptor (er) and progesterone receptor (pr) negative (\< 1% by immunohistochemistry) and human epidermal growth factor receptor 2 (her2)-negative (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization \[fish\] negative) * metastatic disease or locally-advanced disease not amenable to curative intent treatment * adequate hepatic, renal, cardiac, and hematologic function * eastern cooperative oncology group (ecog) performance status 0-1 * recovery to baseline or ≤ grade 1 common terminology criteria for adverse events (ctcae) version.4.0 key exclusion criteria: * known brain metastases or central nervous system (cns) cancer unless adequately treated with radiotherapy and/or surgery and stable for ≥ 2 mo * unable to receive oral medications * known hypersensitivity to cremophor®-based agents * major surgery within 28 days of cycle 1 day 1

Keywords: african ancestry african american cb-839 glutaminase inhibitor glutaminase tnbc tumor metabolism glutamine
diagnostic value of hand ultrasound in assessment of rheumatoid arthritis

Conditions: Patient's With Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is one of the most common autoimmune rheumatic diseases, affecting one in 100 individuals worldwide. it is considered a complex systemic multifactorial inflammatory process in which the immune system targets synovial joints and causes mild to severe joint destruction with extra-articular manifestations. if left untreated, ra leads to deformity, considerable disability, and major comorbid conditions, including cardiovascular disease and increased mortality. early treatment with targeted therapies can alter long-term outcomes by minimizing disease activity, preventing joint damage and disability, and improving patients' quality of life.


Eligibility criteria:
inclusion criteria: 1. adult-onset disease. 2. patients who fulfill the 2010 american college of rheumatology/european league against rheumatism classification criteria for rheumatoid arthritis. exclusion criteria: 1. any patient with any collagen disease rather than rheumatoid arthritis. 2. patients with joints deformities.
pos-cuti: study on complicated urinary tract infections

Conditions: Urinary Tract Infections

Summary: urinary tract infections (uti) are among the most common infectious diseases and the most frequent source of community, healthcare-associated and nosocomial bacteraemia. they are associated with significant morbidity and mortality. due to the high frequency of uti, they have a major impact on antibiotic use and the antimicrobial resistance of prominent uti pathogens is of recognised importance. therefore, utis, and particularly complicated urinary tract infections cutis, are a target for repurposing of old and neglected drugs, new drug development and non-antibiotic therapeutic and preventive approaches.


Eligibility criteria:
inclusion criteria: * a documented microbial pathogen on culture of blood or urine according to standards of interpretation regarding to the type of infection, pathogen, quantitative culture results and sample. guide for adequate interpretation is detailed in lab manual. however, if the local laboratory uses diferent microbiological criteria, patients will be elegible and the criteria used will be collected and * local and systemic signs and symptoms of uti including at least one of these two: (a) fever (i.e.,temperature greater than 38ºc), chills or malaise; and (b) flank pain, back pain, costo-vertebral angle pain or tenderness, dysuria or urinary urgency, and * it occurs in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of catheterization, including (but not limited to) presence of a urinary catheter; 100 ml or more of residual urine after voiding (neurogenic bladder); obstructive uropathy (nephrolithiasis, fibrosis); azotemia caused by intrinsic renal disease; urinary retention, including retention caused by benign prostatic hypertrophy. * patients with pyelonephritis or bacteremia with a urinary tract source, regardless of underlying abnormalities of the urinary tract, are also to be included. * patients with urinary catheter presenting with fever, bacteriuria and bacteraemia caused by the same urinary pathogen can be included if other sources of bacteraemia are reasonably discarded. * depending on the country regulation: the patient, family or legally authorised representative signed the informed consent to participate or; notification of non-objection to the use of pseudo-anonymized personal and medical data. exclusion criteria: * patients with a life expectancy previous to development of cuti \<30 days and those exclusively under palliative care in whom any eventually needed invasive procedure would not be performed. * patients who died in \<48 hours since the presentation with cuti * patients participating in rct for treatment of cuti * \>96 hours since from the clinical diagnosis of cuti. i.e. \>96 hours from positive urine/blood culture.

Keywords: uti european clinical research network randomized itus research activities
an efficacy study of pomalidomide in patient with multiple myeloma in routine clinical practice

Conditions: Multiple Myeloma

Summary: this study, a national, multicenter, observational, ambispective, non-interventional study, will be conducted in french hospitals prescribing pomalidomide and already participating in the ongoing imnovid registry. this study will add to the registry. indeed, pomalidomide-prescribing physicians and pharmacists dispensing pomalidomide have to enter into the imnovid registry all patients who have been prescribed this drug since the date on which it was marketed regardless of the initiation date of pomalidomide or the indication for which it was prescribed.


Eligibility criteria:
inclusion criteria: * adult patient (age ≥ 18 yrs), * diagnosed with multiple myeloma (measurable or not), * in whom pomalidomide treatment was first initiated between october 1, 2014, and september 30, 2019, * patient already included in the imnovid registry, * having received oral and written information about the study, and having given their consent to participate. exclusion criteria: * previous participation in a clinical trial with pomalidomide, * treatment with pomalidomide in a previous line, * simultaneous participation in a clinical trial.

Keywords: multiple myeloma pomalidomide efficacy
effectiveness of scapular exercises compared to conventional treatment in shoulder pain

Conditions: Shoulder Pain; Scapular Dyskinesis

Summary: the contribution of the scapula to shoulder joint movement is great. the contribution of the scapula bone is more prominent, especially in overhead activities. therefore, the position and movement of the scapula are generally examined in people with shoulder disease. scapula-focused exercises are used in patients with shoulder problems. however, some studies focused on the effectiveness of scapula-focused exercises on shoulder problems. thes studies fundings are controversial. scapular dyskinesis has not been evaluated in these studies. no study has set the condition of having scapular dyskinesis as an inclusion criterion. scapular-focused exercises are expected to have a greater effect especially on patients with scapular dyskinesis. therefore, the aim of this study is to examine the effectiveness of scapula-focused exercises on patients with shoulder pain and obvious scapular dyskinesis.


Eligibility criteria:
inclusion criteria: * having shoulder pain for at least 1 month * having obvious scapular dyskinesia * having a shoulder rom (range of motion) at least 120º * being 18 years of age or older exclusion criteria: * having received any shoulder treatment in the last 6 months * having an acromioclavicular joint problem * having a diagnosis of frozen shoulder * having a fracture in the shoulder area * having a major rotator cuff muscle tear * having a diagnosis of calcific rotator cuff tendinopathy * having a neurological or rheumatological disease

Keywords: shoulder pain obvious scapular dyskinesis conventional treatment scapular exercises effectiveness
comparative efficacity of ephedrine versus norepinephrine to correct anesthesia induction related hypotension

Conditions: Hypotension on Induction

Summary: hypotension occurs frequently after anesthesia induction and is more frequent in patients with chronic renal insufficiency. this hypotension occurs most frequently during the 20 minutes after anesthesia induction. hypotension is commonly corrected by ephedrine bolus injection. however, presynaptic noradrenaline reserve may be lower in patients with chronic renal insufficiency rendering this treatment less effective. another drug commonly used is norepinephrine, which action is independent of presynaptic noradrenaline storage. the primary hypothesis is that in patients with chronic renal insufficiency, bolus injection of norepinephrine will be more effective then ephedrine injections to correct hypotension after anesthesia induction. 60 patients with a glomerular filtration rate less than 45 ml/min/m2 (kdigo classification less than grade 3b) will be included in this prospective double blind trial. all patients will be anesthetized by target-controlled infusion of propofol adjusted to a patient state index (measured by sedline, masimo) of 25-50. sufentanil injection will be based on noxious stimuli according to the attending anesthesiologist's judgement. non-invasive blood pressure will be measured at the pre-anesthesia clinic, before induction and every minute up to 20 minutes post anesthesia induction. episodes of hypotension, defined as a mean arterial blood pressure less than 65 mm hg, will be treated either by a bolus injection of 6 mg ephedrine or a bolus injection of 6 mcg norepinephrine, which are equipotent doses. seringues containing either ephedrine 3 mg/ml or norepinephrine 3 mcg/ml will be prepared by an anesthesia nurse not involved in the care of the patient and labeled as "vaso-irc-inclusion number". randomization will be done by a computer generated list in a block randomization of 5. primary outcome is the number of boluses needed to maintain arterial blood pressure above a mean of 65 mm hg.


Eligibility criteria:
inclusion criteria: * elective non-cardiac surgery * general anesthesia * chronic renal insufficiency defined as a glomerular filtration rate \< 45 ml/min/m2 exclusion criteria: * cardiac insufficiency with a left ventricular ejection fraction \< 50% * severe cardiomyopathy * severe cardiac valvular disease * use of enzyme converting inhibitors or sartans less than 24h before surgery * use of alpha2 antihypertension medication * chronic treatment by: noradrenaline or dopamine recapture inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors
analysis of ms patients who have had greater than 60 infusions of natalizumab

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to explore the safety and efficacy data in clinic patients who have been treated with natalizumab for more than 60 continuous infusions.

this is a retrospective chart review and data analysis of patients at the ms center of northeastern new york , p.c., who have had greater than 60 continuous infusions prior to the irb approval date. only records that are in existence at the time of the irb review and approval will be accessed for inclusion in the data analysis.

Eligibility criteria:
inclusion criteria: * multiple sclerosis patients treated with long term use of natalizumab--60 or more infusions (5 years) exclusion criteria: * patients who do not have 60 or more infusions (5 years) of natalizumab.

Keywords: natalizumab tysabri
observation study on the efficacy of yiqi gubiao pill in the treatment of chronic obstructive pulmonary disease secondary to active pulmonary tuberculosis

Conditions: Tuberculosis-related Obstructive Pulmonary Disease

Summary: tuberculosis-related obstructive pulmonary disease (topd), as a high-burden disease in most countries, poses difficulties in the diagnosis and treatment of the disease when coexisting, and increases the risk of death for patients. preliminary studies have shown that yiqi gubiao wan has significant effects in relieving cough, alleviating asthma, expectorating phlegm, and delaying airway obstruction. the purpose of this study is to verify the therapeutic effect of yiqi gubiao pill on patients with topd through rigorous methodological design and to evaluate its safety. we will conduct a prospective, double-blind, randomized controlled trial. first, participants will be randomly assigned 1:1 to the yiqi gubiao pill treatment group and the yiqi gubiao pill placebo control group. this will be followed by a 12-week treatment. during the treatment period, we will measure and record the patients' lung function and quality of life. we will also score the patients' tcm symptoms. finally, the safety of the medication will be assessed.


Eligibility criteria:
inclusion criteria: - patients who meet the following criteria will be included: 1. age 40-75 years old; 2. meet the western medical diagnostic criteria and typing standards for active ptb; 3. patients who have not taken steroids, anti-tuberculosis drugs, or other immunosuppressants and have not undergone desensitization treatment within one month. 4. have understood the treatment methods and voluntarily signed the informed consent form. exclusion criteria: - patients who meet any of the following criteria will be excluded: 1. patients with pneumothorax, pleural effusion, lung cancer and other serious lung diseases; 2. patients with severe cardiovascular and cerebrovascular, hepatorenal and hematopoietic diseases; 3. mentally ill; 4. patients with tumors; 5. congenital or acquired immunodeficiency.

Keywords: pulmonary tuberculosis yiqi gubiao pills chronic obstructive pulmonary disease randomized double-blind placebo-controlled trial
standardized emergency care for community acquired pneumonia (cap)

Conditions: Community Acquired Pneumonia; Pneumonia; Infection

Summary: community acquired pneumonia (cap) is associated with a high in-hospital mortality. standardization of diagnostics and adherence to sepsis bundles in the emergency department (ed) are associated with reduced mortality in patients with sepsis. investigators examined whether the introduction of standardized care bundles and check lists in the ed are associated with a reduced mortality rate in patients hospitalized for cap. this is an observational trial. the investigators retrospectively analyzed performance indicators of 2819 consecutive patients with cap admitted to the nuremberg hospital, germany, from 2008 to 2009. at the turn of the year, implementation of cap care bundles took place including interprofessional education, checklists and institutionalized feedback. primary endpoint was in-hospital mortality of cap patients. after the implementation of cap care bundles in the ed, mortality of affected patients was significantly lower in 2009 compared to 2008. this study should demonstrate that the implementation of a standardized cap care bundle in the ed is associated with a risk reduction in affected patients. standardization of diagnostic and therapeutic processes in the ed therefore improves the outcome of patients hospitalized for cap.


Eligibility criteria:
inclusion criteria: * all patients with community acquired pneumonia exclusion criteria: * exacerbation of chronic obstructive pulmonary disease * malignancy * immunosuppression * neutropenia

Keywords: community acquired pneumonia emergency department standardized care reduced mortality crb-65 risk classes antibiotic therapy
comparison of insulin detemir, insulin aspart and biphasic insulin aspart 30 with oad treatment in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this research study is to compare the efficacy (reduction in hba1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current oad (oral anti-diabetic drug) treatment in subjects with type 2 diabetes and to verify the safety of use (number and severity of episodes of hypoglycaemia, body weight and side effects).


Eligibility criteria:
inclusion criteria: * type 2 diabetes * insulin naive * on oad treatment for at least 4 months with metformin, a sulphonylurea or a combination * body mass index (bmi) below or equal to 40.0 kg/m2 * hba1c (glycosylated haemoglobin): 7.0%-10% (both inclusive) exclusion criteria: * proliferative retinopathy * recurrent major hypoglycaemia * cardial problems * uncontrolled hypertension * impaired hepatic or renal function